Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 116

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 116
---
 76.54 
    APL 
    N/A 
    t(15;17)
  
    200015508 
    Progressive 
    Imatinib 400 mg. 
    63 
    Female 
    White 
    Non-Hispanic/Latino 
    50 
    Intermediate 
    VAF < 50% 
    N/A
  
    200019095 
    Newly Diagnosed 
    none 
    63 
    Female 
    White 
      
    82.65 

    200013114 
    Newly Diagnosed 
    none 
    83 
    Male 
    White 
      
    56.8 
      
    NRAS 

    130800395 
    Newly Diagnosed 
    none 
    72 
    Female 
    White 
      
    75.7 
    Adverse 
    TET2, ASXL1, TP53 

    200015280 
    Newly Diagnosed 
    none 
    67 
    Female 
    White 
      
    15.3 
      
    ETV6, BCORL, KRAS 

    200009820 
    Newly Diagnosed 
    none 
    31 
    Male 
    White 
      
    85.7 
      
    KRAS 

    200009056 
    Newly Diagnosed 
    none 
    21 
    Female 
    White 
      
    94.8 
    Adverse 
    DNMT3A, BCORL1, TP53 

13

AML from bone marrow or PBMC have elevated cell surface TIM-4-L

CER-1236 T cells were also
observed to generate potent anti-cancer responses against myeloid malignancies. AML is a heterogenous, and aggressive hematopoietic malignancy
characterized by the rapid buildup of immature myeloid cells in the bone marrow and blood. We used AML cell lines depicted in the graph
below, Kasumi-1 and MV-4-11, to demonstrate cytotoxic anti-AML responses in co-culture studies with CER-1236. Similar to in vitro cytotoxicity
results observed with B cell malignancy and NSCLC cell lines, we show the addition of CER-1236 alone to AML cell lines demonstrates